Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease
Joint Authors
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-2, 2 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-11-08
Country of Publication
Egypt
No. of Pages
2
Main Subjects
Abstract EN
We present a case of refractory ileocolonic Crohn’s disease in a 27-year-old female treated with dual ustekinumab and vedolizumab biologic therapy.
She had mucosal healing for the first time in 13 years after a 10-month treatment of ustekinumab overlapped with 6 months of vedolizumab.
No side effects were observed during the 6 months of dual biologic therapy.
Short-term dual biologic therapy may be considered as a treatment option for induction of remission in refractory cases of Crohn’s disease.
American Psychological Association (APA)
Liu, Eddie Y.& Loomes, D. E.. 2017. Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease. Case Reports in Medicine،Vol. 2017, no. 2017, pp.1-2.
https://search.emarefa.net/detail/BIM-1146776
Modern Language Association (MLA)
Liu, Eddie Y.& Loomes, D. E.. Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease. Case Reports in Medicine No. 2017 (2017), pp.1-2.
https://search.emarefa.net/detail/BIM-1146776
American Medical Association (AMA)
Liu, Eddie Y.& Loomes, D. E.. Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease. Case Reports in Medicine. 2017. Vol. 2017, no. 2017, pp.1-2.
https://search.emarefa.net/detail/BIM-1146776
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1146776
